share_log

Biodexa Pharmaceuticals | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

SEC announcement ·  Jan 22 13:00
Summary by Futu AI
On January 22, 2024, Biodexa Pharmaceuticals PLC, a clinical stage biopharmaceutical company, issued a shareholder letter through CEO and CFO Stephen Stamp, outlining the company's achievements in 2023 and its strategic outlook for 2024. The letter, which serves as a progress report, was released as part of a Form 6-K filing with the United States Securities and Exchange Commission. Biodexa, which transitioned from Midatech Pharma to a NASDAQ-listed entity with a broader therapeutic portfolio, highlighted the in-licensing of tolimidone, a clinical stage molecule for Type 1 diabetes. The company plans to announce data from an in vitro study of tolimidone and initiate a Phase IIa study in 2024. Additionally, Biodexa reported on MTX110, a treatment for recurrent Glioblastoma Multiforme and Diffuse Midline Glioma, with...Show More
On January 22, 2024, Biodexa Pharmaceuticals PLC, a clinical stage biopharmaceutical company, issued a shareholder letter through CEO and CFO Stephen Stamp, outlining the company's achievements in 2023 and its strategic outlook for 2024. The letter, which serves as a progress report, was released as part of a Form 6-K filing with the United States Securities and Exchange Commission. Biodexa, which transitioned from Midatech Pharma to a NASDAQ-listed entity with a broader therapeutic portfolio, highlighted the in-licensing of tolimidone, a clinical stage molecule for Type 1 diabetes. The company plans to announce data from an in vitro study of tolimidone and initiate a Phase IIa study in 2024. Additionally, Biodexa reported on MTX110, a treatment for recurrent Glioblastoma Multiforme and Diffuse Midline Glioma, with expected data announcements in 2024. Another focus is MTD217, targeting leptomeningeal disease, with preclinical data expected by the end of the first quarter of 2024. Biodexa raised $6.0 million in December 2023, which will support the delivery of preclinical and clinical data for its pipeline that includes five programs, four of which are at the clinical stage. The company's R&D facility is based in Cardiff, UK.

This announcement is a separate document:

Doc 1

Doc 2

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.